| 4.1 Cardiovascular mortality |
19 |
21763 |
Risk Ratio (M‐H, Random, 95% CI) |
0.73 [0.63, 0.85] |
| 4.2 Cardiovascular mortality ‐ Type of beta‐blocker |
19 |
21763 |
Risk Ratio (M‐H, Random, 95% CI) |
0.73 [0.63, 0.85] |
| 4.2.1 Atenolol |
1 |
757 |
Risk Ratio (M‐H, Random, 95% CI) |
0.45 [0.19, 1.09] |
| 4.2.2 Acebutolol |
1 |
607 |
Risk Ratio (M‐H, Random, 95% CI) |
0.41 [0.22, 0.79] |
| 4.2.3 Alprenolol |
1 |
162 |
Risk Ratio (M‐H, Random, 95% CI) |
0.15 [0.02, 1.15] |
| 4.2.4 Carvedilol |
1 |
794 |
Risk Ratio (M‐H, Random, 95% CI) |
1.22 [0.37, 3.96] |
| 4.2.5 Metoprolol |
4 |
3383 |
Risk Ratio (M‐H, Random, 95% CI) |
0.86 [0.67, 1.10] |
| 4.2.6 Oxprenolol |
3 |
3817 |
Risk Ratio (M‐H, Random, 95% CI) |
0.81 [0.45, 1.46] |
| 4.2.7 Pindolol |
1 |
529 |
Risk Ratio (M‐H, Random, 95% CI) |
0.94 [0.63, 1.40] |
| 4.2.8 Practolol |
1 |
3053 |
Risk Ratio (M‐H, Random, 95% CI) |
0.61 [0.43, 0.87] |
| 4.2.9 Propranolol |
4 |
5321 |
Risk Ratio (M‐H, Random, 95% CI) |
0.73 [0.56, 0.97] |
| 4.2.10 Sotalol |
1 |
1456 |
Risk Ratio (M‐H, Random, 95% CI) |
0.83 [0.58, 1.18] |
| 4.2.11 Timolol |
1 |
1884 |
Risk Ratio (M‐H, Random, 95% CI) |
0.58 [0.45, 0.75] |
| 4.3 Cardiovascular mortality ‐ Different follow‐up |
19 |
21763 |
Risk Ratio (M‐H, Random, 95% CI) |
0.73 [0.63, 0.85] |
| 4.3.1 Between 6 months and 12 months |
7 |
5778 |
Risk Ratio (M‐H, Random, 95% CI) |
0.80 [0.60, 1.08] |
| 4.3.2 Between 1 year and 3 years |
11 |
15191 |
Risk Ratio (M‐H, Random, 95% CI) |
0.69 [0.57, 0.83] |
| 4.3.3 3 years or longer |
1 |
794 |
Risk Ratio (M‐H, Random, 95% CI) |
1.22 [0.37, 3.96] |
| 4.4 Cardiovascular mortality ‐ Registration status |
19 |
21763 |
Risk Ratio (M‐H, Random, 95% CI) |
0.73 [0.63, 0.85] |
| 4.4.1 Post‐registration |
1 |
3837 |
Risk Ratio (M‐H, Random, 95% CI) |
0.74 [0.60, 0.93] |
| 4.4.2 No registration |
17 |
17132 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.60, 0.86] |
| 4.4.3 Pre‐registration |
1 |
794 |
Risk Ratio (M‐H, Random, 95% CI) |
1.22 [0.37, 3.96] |
| 4.5 Cardiovascular mortality ‐ Industry vs non‐industry funding |
19 |
21763 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.72 [0.64, 0.80] |
| 4.5.1 Industry‐funded trials or unknown funding |
16 |
20061 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.73 [0.65, 0.81] |
| 4.5.2 Non‐industry‐funded trials |
3 |
1702 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.36, 0.85] |
| 4.6 Cardiovascular mortality ‐ Subacute vs non‐acute phase |
19 |
21763 |
Odds Ratio (M‐H, Random, 95% CI) |
0.71 [0.60, 0.84] |
| 4.6.1 Beta‐blockers administered within 7 days following acute myocardial infarction (subacute phase) |
2 |
1354 |
Odds Ratio (M‐H, Random, 95% CI) |
0.70 [0.40, 1.22] |
| 4.6.2 Beta‐blockers administered after 7 days following acute myocardial infarction (non‐acute phase) |
17 |
20409 |
Odds Ratio (M‐H, Random, 95% CI) |
0.71 [0.59, 0.84] |
| 4.7 Cardiovascular mortality ‐ Heart failure vs no heart failure |
19 |
21763 |
Risk Ratio (M‐H, Random, 95% CI) |
0.73 [0.63, 0.85] |
| 4.7.1 Trials specifically excluding heart failure participants |
9 |
7930 |
Risk Ratio (M‐H, Random, 95% CI) |
0.61 [0.48, 0.79] |
| 4.7.2 Trials specifically excluding heart failure participants but likely not adhering to this |
10 |
13833 |
Risk Ratio (M‐H, Random, 95% CI) |
0.80 [0.66, 0.96] |
| 4.8 Cardiovascular mortality ‐ 'Best‐worst case scenario' |
19 |
21770 |
Risk Ratio (M‐H, Random, 95% CI) |
0.71 [0.60, 0.83] |
| 4.9 Cardiovascular mortality ‐ 'Worst‐best case scenario' |
19 |
21770 |
Risk Ratio (M‐H, Random, 95% CI) |
0.75 [0.63, 0.90] |
